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Summary The camptothecins are a new class of chemotherapeutic agents which have a novel mechanism of
action targeting the nuclear enzyme topoisomerase I. Knowledge of the structure-activity relationships of the
parent compound camptothecin has led to the development of effective soluble analogues with manageable
toxicities. Broad anti-tumour activity shown in preclinical studies has been confirmed in phase I/II studies for
irinotecan and topotecan. Two other derivatives, 9-aminocamptothecin and GI 14721IC, are undergoing phase
I and early phase II evaluation. Although camptothecin is a plant extract, it and most of its derivatives are not
affected by the classic p_gpMDRI mechanism of resistance which may allow the development of novel
combination chemotherapeutic regimens. Important areas of future endeavour will include the development of
rational combination regimens and the pursuit of randomised trials. Based on single agent data, colorectal
cancer and non-small-cell lung cancer should be the focus for future irinotecan studies. Small-cell lung cancer
and ovarian carcinoma are logical tumour types to pursue with topotecan. Both 9-aminocamptothecin and GI
14721 IC are too early in their clinical evaluation to make recommendations about their future roles. Finally,
the unfolding story ofcamptothecin analogue development will give important insights into the predictive value
of preclinical observations on relative efficacy, schedule dependency, combination strategies and resistance
mechanisms which have helped determine the strategies for clinical evaluation of these agents.
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More than 30 years ago, an extract from the Chinese tree
Camptotheca acuminata was found to have anti-tumour
activity in experimental systems (Wall et al., 1966). The
active compound, camptothecin, being insoluble in aqueous
solution, was modified and its water-soluble sodium salt was
evaluated in clinical studies in the late 1960s and early 1970s.
Leucopenia and thrombocytopenia were dose-limiting toxi-
cities (Muggia et al., 1972). Despite promising anti-tumour
activity in phase I studies, results in phase II trials in patients
with gastrointestinal malignancies (Moertel et al., 1972) and
melanoma (Gottlieb, 1972) indicated the drug was ineffective
and highly toxic. Myelosuppression, vomiting, diarrhoea and
sterile haemorrhagic cystitis were often severe and, as a
result, further clinical testing of camptothecin ceased.
Several developments in the late 1980s renewed interest in
camptothecin: topoisomerase I was identified as the cellular
target of the drug (Hsiang et al., 1988); the structure-activity
relationship was determined for camptothecin (Jaxel et al.,
1989), leading to the development of effective, water-soluble
synthetic and semisynthetic derivatives (Wall et al., 1993);
and topoisomerase I levels were found to be higher in some
tumour tissues compared with the normal tissue counterpart
(Giovanella et al., 1989; Van der Zee et al., 1991). Currently
camptothecin and four analogues: topotecan, irinotecan
(CPT-l1), 9-aminocamptothecin and GI 147211C (GG211)
are undergoing clinical evaluation. During the past 25 years,
knowledge of topoisomerase biochemistry, genetics, molecu-
lar biology and interaction with inhibitors has increased
exponentially and these will be reviewed with the results of
preclinical and clinical evaluations of camptothecin and its
derivatives.
DNA topoisomerase I
Topoisomerases are nuclear enzymes that modulate the three-
dimensional structure of DNA by inducing transient breaks
that allow unwinding of supercoiled DNA (reviewed in
Pommier, 1993). Topoisomerase I is a 100 000 kDa protein
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which relaxes positive and negative supercoils of DNA
arising during DNA and RNA synthesis by making transient
single-stranded breaks in DNA (Champoux, 1976). Intense
research has clarified the camptothecin-topoisomerase I-
DNA interaction. The drug binds to and stabilises the
topoisomerase I enzyme-DNA cleavable complex after
DNA cleavage preventing resealing of DNA and causing an
accumulation of cleavable complexes (Hsiang et al., 1988,
1989). The subsequent interaction between the advancing
replication fork of DNA and the drug-stabilised cleavable
complex results in an arrest of DNA replication with
formation of double-strand breaks. These in turn activate
endonucleases, triggering further DNA fragmentation and
ultimately cell death (Zhang et al., 1990). Thus, cytotoxicity
is dependent on the expression of topoisomerase I and on
DNA replication. Compared with the levels of the enzyme in
normal tissues, a significant increase of topoisomerase I has
been detected in surgical specimens ofcolon adenocarcinoma,
ovarian and oesophageal carcinoma, in cultures of non-
Hodgkin's lymphoma and leukaemia cells and in xenograft
lines of human colon adenocarcinoma, carcinoma of the
stomach, breast, lung and malignant melanoma (Potmesil,
1994). Cell lines which have high levels of enzyme are
hypersensitive to camptothecin-induced cytotoxicity (Mad-
den, 1992). Conversely, cell lines resistant to camptothecin
may contain qualitatively or quantitatively altered forms of
the target enzyme (Pommier, 1993). Although topoisomerase
I is expressed throughout the cell cycle, cells in S-phase are
1000 times more sensitive than cells in G, or G2-phase to the
cytotoxicity of camptothecins reflecting the need for DNA
replication for drug efficacy (Del Bino et al., 1991). Although
much is known, our understanding of the mechanism of
activity of these agents might be incomplete. These agents are
active in human tumour xenografts that typically have low S-
phase fractions and studies have shown that the fraction of
cells killed by a brief exposure to camptothecin is sometimes
larger than the S-phase fraction of the cell population, thus
other cellular effects of camptothecins may be linked to
cytotoxicity (O'Connor et al., 1991).
Structure-activity experiments have defined the features
of the molecule critical for cytotoxicity. Camptothecin has a
heterocyclic five-ring structure with a lactone moiety and anCamptothecins in cancer treatment
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S-hydroxyl moiety on ring E (Figure 1). Camptothecin
lactone exists in a pH-dependent equilibrium with an open
ring carboxylate form. At physiological pH 90% of the drug
exists as carboxylate. Both the pentacyclic ring structure of
camptothecin, and the lactone and hydroxyl moieties are
required for cytotoxicity as molecules with fewer than five
rings, or bearing either a 20(R) hydroxyl or the open ring
carboxylate are biologically inactive (Hertzberg et al.,
1989a,b). Substitutions at positions 9 or 10 by amino or
hydroxyl groups lead to compounds with equal or greater in
vivo activity than the parent compound (Wani et al., 1980,
1987). Knowledge of these features has led to the
development of analogues of camptothecin which are both
water soluble and effective. Four analogues are now
undergoing clinical evaluation: irinotecan, topotecan, 9-
aminocamptothecin and GI 147211 (GG21 1).
Irinotecan (CPT-ll)
Preclinical studies
The first of the water-soluble analogues is irinotecan (CPT-
11) or 7-ethyl-10-(4-[1-piperidino]-l-piperidino)methyl-10-hy-
droxycamptothecin. Irinotecan, a prodrug with limited
activity, is converted in plasma by de-esterification into SN-
38 which has 1000 times the potency of the parent compound
(Kawato et al., 1991a).
Irinotecan is active against a diverse array of tumour cell
lines in vitro and in vivo. The SN-38 metabolite is a more
effective inhibitor of topoisomerase I and more cytotoxic
toward HT-29 human colon carcinoma cells in culture than
camptothecin, 9-aminocamptothecin and topotecan (Taniza-
wa et al., 1994). Irinotecan, when given by intraperitoneal,
intravenous or oral routes, showed substantial activity
against a broad spectrum of mouse and human tumour
xenografts including human cancer xenograft lines resistant
to topotecan, vincristine or melphalan (Kunimoto et al.,
1987). Interestingly, sensitivities of some tumour cell lines to
irinotecan were independent of their ability to produce SN-38
suggesting that cytotoxicity is not solely dependent on the
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production of the metabolite (Kawato et al., 1991b). Unlike
9-aminocamptothecin and topotecan, the efficacy of irinote-
can was not substantially influenced by administration
schedule in preclinical studies (Furuta, 1990).
Clinical studies of irinotecan
Clinical evaluation of irinotecan is well advanced. Phase I
trials (Table I) were conducted in Japan and more recently in
the United States and Europe on several schedules: 30 min
infusion every week and every 3 weeks; 30-90 min infusion
daily for 3 days every 3 weeks; 90 min infusion every week
and 3 weeks; and 120 h continuous intravenous infusion
every 3-4 weeks. Dose-limiting toxicities were somewhat
dependent on the treatment schedule. Dose-limiting leucope-
nia, neutropenia and diarrhoea were prominent in single-dose
regimens, while gastrointestinal toxicities prevailed with c.i.v.
schedules. Diarrhoea is the most significant gastrointestinal
toxicity and may occur early or late following treatment. The
early syndrome begins during or shortly after the infusion of
irinotecan and is often associated with flushing, sweating,
nausea, vomiting and abdominal cramps. Both inhibition of
acetylcholinesterase at muscarinic receptors (Kawato et al.,
1993) and stimulation of the nicotinic receptors in autonomic
ganglion cells (Gandia et al., 1993) have been postulated as
mechanisms. It can be managed by the administration of
diphenhydramine or atropine with a serotonin antagonist
such as ondansetron. Late diarrhoea begins 1-3 weeks after
treatment and may last 5-7 days. Its occurrence is
unpredictable and it may be severe. It is refractory to most
antidiarrhoeal agents including opiates, atropine and octreo-
tide but it may respond to high-dose loperamide with or
without the enkephalinase inhibitor acetorphan (Hagipantelli
et al., 1995). In one small study, early aggressive treatment
with loperamide 2 mg every 2 h (24 mg per 24 h) until 12 h
without a bowel movement reduced the incidence of severe
diarrhoea to 6% (Abigerges et al., 1994). Other toxic effects
of irinotecan included thrombocytopenia, eosinophilia,
anaemia, alopecia, fatigue, transient elevation of liver
function tests, rash and mucositis. Rarely, cases of
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Figure 1 CPT, camptothecin; TPT, topotecan; 9-AC, 9-aminocamptothecin; CPT- 1, irinotecan; GG21 1, GI14721IC.Camptothecins in cancer treatment
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interstitial pneumonitis have occurred in previously treated
patients with lung cancer.
The pharmacokinetics of irinotecan are complex. In
plasma, carboxylesterases rapidly convert the prodrug into
SN-38 and both irinotecan and SN-38 are converted by pH-
dependent hydrolysis from lactone to carboxylate forms.
Concentrations of the irinotecan lactone in plasma is almost
two orders of magnitude higher than that of SN-38 and both
lactone forms represent 44% and 50% of the total drug and
metabolite detectable in plasma (Rowinsky et al., 1994a).
Peak plasma levels and AUC of irinotecan correlate well with
dose (De Forni et al., 1994). The AUC of SN-38 correlates
with the AUC but not the dose of irinotecan. The reported
terminal half-life of irinotecan is 5.2-9.3 h, and the mean
residence times for it and SN-38 are 9.1 and 10.0 h.
Hydrolysis of irinotecan and SN-38 lactone is less than for
topotecan and 9-aminocamptothecin with 33-66% remaining
intact at 24 h after infusion of irinotecan. The maintenance
of biologically relevant concentrations of SN-38 for long
durations may explain the observation that anti-tumour
efficacy of irinotecan is not schedule dependent. There is
significant interpatient variability in the conversion of
irinotecan to SN-38, implying that dose increases may not
lead to proportional increases in cytotoxicity.
Biliary and urinary excretion are both important routes of
elimination. In humans 37+4% of the drug is detected in
urine in 48 h (Rowinsky, 1994a). Both irinotecan and SN-38
undergo glucuronic acid conjugation and are eliminated in
bile (Narita et al., 1993; Gupta et al., 1994). fl-Glucuronidase
of intestinal microflora can cleave the glucuronide and free
intestinal SN-38 which may play a role in producing the late
diarrhoea. Indirect estimates of biliary concentration of SN-
38 and its glucuronide have shown good correlation between
the concentration of SN-38 and the occurrence of late
diarrhoea (Araki et al., 1993).
In single agent phase II trials (Table II), irinotecan was
active against a wide range of carcinomas and lymphomas.
Activity was observed using schedules of 100-150mg m-2
week-1 and 350 mg m-2 every 3 weeks. The response rates
appear to favour weekly administration but direct compar-
isons between the two schedules have not been made. Of
particular interest are the results offive trials in patients with
metastatic colorectal cancer where response rates have ranged
from 14% to 32%. Similar levels of activity have been seen in
untreated colorectal patients, patients previously treated with
5-FU and patients who were treated after progressing on 5-
FU (Bugat et al., 1995). Response rates of 34% and 36%
were observed in untreated patients with non-small-cell lung
cancer. Complete and partial remissions were seen in 24% of
ovarian cancer and 23% of breast cancer patients who had
received prior chemotherapy. Results of three studies in
patients with cervical cancer have been mixed, perhaps
reflecting different schedules and patient populations. On
the weekly schedule response rates of 24-27% were observed
in patients previously treated with cisplatin but 0% in
patients who were refractory to cisplatin. A response rate
of 15% was observed in chemotherapy-naive patients on the
3 weekly schedule but 24% in the subset of 21 patients who
had measurable disease outside previously irradiated fields.
Partial responses were seen in 23% of patients with advanced
gastric cancer, 40% of patients with small-cell lung cancer
and in 39% with non-Hodgkin's lymphoma. Thus, irinotecan
has impressive activity in many malignancies particularly
colorectal carcinoma, non-small-cell lung cancer and cervical
carcinoma. Toxic effects are usually manageable but late
diarrhoea may be severe despite maximal medical therapy.
Because of this it may be challenging to combine this drug
with other cytotoxic agents particularly those with similar
toxicities. A direct comparison of the weekly and 3 weekly
schedule is an obvious question to be addressed in a
comparative trial.
Future directions
Future study of irinotecan will be likely to fall into three
major areas: the pursuit of effective (preferably mechanism-
based) methods of overcoming the late diarrhoea, the
development of rational, safe combination regimens (see
section on Combination treatment) and the randomised
comparison of irinotecan-based regimens with standard
therapy. The tumour types which ought to be the focus of
the initial group of comparative trials include both colorectal
cancer and non-small-cell lung cancer based on the single
agent data in these diseases.
Secondary areas of endeavour which merit evaluation
include further phase II testing, particularly in those tumour
types with supportive preclinical data such as sarcoma and
glioma, and the development of a better understanding of the
pharmacokinetic/dynamic relationship of the drug to toxic
and efficacy outcomes.
Topotecan
Preclinical studies
Topotecan (9-(dimethylamino)methyl-10-hydroxycamptothe-
cin) is a camptothecin derivative having aqueous solubility
conferred by the charged amino group on the 9-substituent.
When tested against a variety of transplantable mouse and
human tumours, topotecan demonstrated anti-tumour
Table I Phase I studies of irinotecan (CPT-l1)
MTD Phase II
Reference Schedule (mg m-2 day-1) (mg m-2) Limiting toxicity Responses
Taguchi et al. (1990) 60 min i.v. q28d 250 200 Neutropenia Not reported
Rowinsky et al. (1994a) 90 min i.v. q2ld 290 240 Neutropenia, nausea, 1 PR rectal
vomiting 1 PR cervix
1 PR RCC
Abigerges et al. (1994) 30 min i.v. q2ld >600 ND ND 4 PR colon
1 PR cervix
De Forni et al. (1994) 30 min i.v. qwk 145 115 Neutropenia 1 PR oesophagus
Negoro et al. (199la) 90 min i.v. qwk 150 100 Leucopenia, diarrhoea 2 PR NSCLC
Rothenberg et al. (1993) 90 min i.v. qwkx4 180 150 Diarrhoea 2 PR colon
q6wk
Lestingi et al. (1995) 90 min i.v. qwkx4 175 145* Neutropenia, 1 PR gastric
q6wk diarrhoea
Ohe et al. (1992) 120 h c.i.v. q3-4wk 40 30 Diarrhoea Not reported
Clavel et al. (1992) 30-90 min i.v. x 3d 145 100 Neutropenia 1 PR mesothelioma
q2ld 1 PR breast
MTD, maximum tolerated dose; PR, partial response; ND, not determined; RCC, renal cell carcinoma; NSCLC, non-small-cell
ling carcinoma; c.i.v., continuous intravenous infusion; *G-CSF and aggressive antidiarrhoeal support.Camptothecins in cancer treatment
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activity when administered intravenously, intraperitoneally,
subcutaneously or orally (McCabe, 1994). Preclinical testing
indicated that, in topotecan-sensitive tumours, longer
exposure to the drug increased the magnitude of response
(Burris et al., 1992; Friedman et al., 1994). This could
indicate that, in the clinic, more prolonged schedules of
administration might be superior to short infusions.
Clinical studies of topotecan
Based on the results or preclinical screening, topotecan
entered phase I studies in the United States and Europe
(Table III). Short, intermediate and prolonged infusion
schedules have been studied including: single intravenous
injection every 21 days; 30 min infusion on 5 consecutive
days every 21-28 days; 24, 72, 96 and 120 h continuous
intravenous infusions every 21-28 days; and a 21 day
continuous intravenous infusion every 28 days. In all studies
myelosuppression was dose-limiting although the pattern of
myelosuppression varied with the method of administration.
Intermittent bolus and short infusion schedules resulted in
non-cumulative neutropenia as the predominant toxicity,
whereas prolonged continuous infusions were followed by
neutropenia, thrombocytopenia and anaemia. Non-haemato-
logical toxic effects were generally mild and included
alopecia, nausea, vomiting, diarrhoea, elevations in hepatic
enzymes, mucositis, skin rash and fatigue.
Pharmacokinetic studies of topotecan show the drug is
rapidly hydrolysed in plasma to the open-ring form following
intravenous administration (Rowinsky et al., 1992). The
plasma clearance is biexponential with a terminal half-life of
3 h. Renal elimination is important as 40% of the drug is
excreted in the urine Within the first 24 h of treatment. There
is a good correlation between the AUC of total topotecan
(lactone plus hydroxyacid) and the grade of neutropenia in
patients with normal or impaired renal or hepatic function
(Grochow et al., 1994). Patients with reduced creatinine
clearance require dose adjustment as they are at increased
risk of toxicity from topotecan. However, hyperbilirubinae-
mia does not alter topotecan disposition or toxicity and no
dose adjustment is required in patients with serum bilirubin
as high as 170 imol 1-'.
Although the dose-limiting toxicity of topotecan was
neutropenia, attempts to improve dose intensity on the daily
x 5 schedule by using haematopoietic growth factors were
not successful (Murphy et al., 1992; Rowinsky et al., 1992;
Janik et al., 1993).
Since several anti-tumour responses were seen in the daily
x 5 phase I trial, this schedule was selected for phase II
evaluation. Following this decision, the 21-day c.i.v. phase I
trial was completed and also appeared active, thus a limited
number of phase II trials have been initiated with the more
prolonged schedule.
Because of its broad activity in phase I studies, phase II
studies of topotecan were initiated for many different tumour
types (Table IV). In a randomised phase II study comparing
the daily x 5 day schedule to 72 h c.i.v. schedule in
untreated patients with advanced NSCLC, response rate,
median time to progression and median survival favoured the
daily for 5 days schedule (Weitz et al., 1995). In untreated
colorectal cancer an 8% response rate was seen using the 21-
day c.i.v. schedule. This response rate was similar to that
observed in colorectal carcinoma with the daily x 5 day
schedule, but the c.i.v. administration was associated with
significant cumulative myelosuppression and pronounced
anaemia (Creemer et al., 1995). Activity in other tumour
types on the daily x 5 schedule included response rates of
40% and 21% in untreated and previously treated SCLC
respectively, 33% in breast cancer and 27% in head and neck
cancer. In two trials involving heavily pretreated patients
Table II Irinotecan (CPT-11) phase II trials
Evaluable Dose schedule Response
Reference Tumour site patients Prior Rx (mg m 2 dose-') CR PR %
Ohno et al. (l990)a Lymphoma 66 All 40 daily x 3d qwk 9 17 39
Ota et al. (1994) Leukaemia 41 All 15 -20 b.i.d. x 7d q3-4wk 0 2 5
Sakata et al. (1994) Pancreas 35 Some 100 qwk 0 4 11
150 q2wk
Wagener et al. (1994) Pancreas 18 None 350 q3wk 0 3 15
Takeuchi et al. (1991)a Ovary 55 52 CDDP 100 qwk 0 13 24
4 XRT
Cervix 55 30 CDDP 150 q2wk 5 8 24
52 XRT
Kavanagh et al. (1994) Cervix 11 All CDDP 150 qwk x 4wks 1 2 27
q6wks
Potkul et al. (1995) Cervix 14 All CDDP 125 qwkx4wk q6wk 0 0 0
resistant
Chevallier et al. (1995) Cervix 34 No CT 350 q3wks 1 4 15b
Douillard et al. (1995) NSCLC 11 No CT 350 q3ks 0 4 36
Negoro et al. (1991b)a NSCLC 67 None 100 qwk 0 23 34
Masuda et al. (1992) NSCLC 26 All 100 qwk 0 0 0
SCLC 8 None 100 qwk 0 4 50
SCLC 27 All 100 qwk 2 7 33
Bonneterre et al. (1993) Breast 12 All 350 q3wk 1 0 8
Taguchi et al. (1994)a Breast 65 46 CT 100 qwk 1 14 23
Shimada et al. (1993) Colon 63 51 CT 100 qwk 0 17 27
150 q2wk
Pitot et al. (1994) Colon 34 21 CT 125 weeklyx4 0 5 24
q6wk 0 2 15
Rothenberg et al. (1994) Colon 44 All 125 -150 weekly x 4 q6wk 1 10 25
Bugat et al. (1994) Colon 85 All 350 q3wk 2 10 14
Rougier et al. (1994) Colon 35 None 350 q3wk 0 7 20
Conti et al. (1994) Colon 19 None 125 weekly x4 0 6 32
q6wk
Futatsuki et al. (1994) Gastric 60 45 CT 100 qwk 0 14 23
150 q2wk
aStudies with early and late results. bl CR and 3 PR (24%) in 21 patients with measurable disease outside previously
irradiated areas.Camptothecins in cancer treatment
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with carcinoma of the ovary, response rates of 14% and 25%
were seen. In both studies, the majority of non-responding
patients had prolonged disease stabilisation, an observation
reminiscent of results with taxoids in platinum-treated
patients. Minimal activity was observed against carcinomas
of the pancreas, prostate, kidney, NSCLC, melanoma,
mesothelioma, soft-tissue sarcoma and glioma.
Future directions
Based on its promising single agent phase II results, further
studies of topotecan in combination with other effective
cytotoxic agents are warranted in SCLC, breast cancer, head
and neck cancer and ovarian cancer (see section on
Combination treatment). Small-cell lung cancer and ovarian
Table m Topotecan phase I studies
MTD Phase II
Reference Schedule mg m-2 dose-' mg m-2 dosel Limiting toxicity Objective responses
Wall et al. (1992) 30 min i.v. q2ld 22.5 20 Neutropenia None
Hasegawa et al. (1993) 30 min i.v. q2ld 22.5 20 Leucopenia Not reported
Blaney et al. (1993)a 24 h c.i.v. q2ld 7.5b 5.5 Leucopenia, None
thrombocytopenia
Abbruzzese et al. (1993) 24 h c.i.v. q2ld 12.5 1OC Neutropenia None
ten Bokkel Huinink et al. (1992) 24 h c.i.v. q2ld 10.5 8.4 Neutropenia, None
thrombocytopenia
Haas et al. (1994) 24 h c.i.v. qwk 1.75 1.5 Neutropenia 1 PR colon
Pratt et al. (1994)a 72 h c.i.v. q2ld 3.9 3.0 Neutropenia, 1 CR neuroblastoma
G-CSF thrombocytopenia
Sabiers et al. (1993) 72 h c.i.v. qwk 2 2 Myelotoxicity Not reported
72 h c.i.v. q2wk 2.6
Burris et al. (1994) 72 h c.i.v. q2ld 4.8 4.8 Neutropenia, None
120 h c.i.v. q2ld 3.4 thrombocytopenia
Kantarjian et al. (1993)e 120 h c.i.v. q21-28d 11.8 10 Mucositis 2 CR AML
1 CR CML-BC
2 PR AML
Rowinsky et al. (1992) 30 min i.v. x Sd q2ld 2 1.5 Neutropenia 1 CR NSCLC
1 CR ovary
2 PR NSCLC
Saltz et al. (1993) 30 min i.v. x 5d q28d 1.75 1.5 Neutropenia 1 PR oesophagus
1 PR CUP
Verweij et al. (1993) 30 min i.v. x 5d 1.5 1.5 Leucopenia 1 PR SCLC
q2ld 1 PR NSCLC
1 PR pancreas
Tubergen et al. (1994) 30 min i.v. x 5d 2.4 2.0 Neutropenia, None
q2ld thrombocytopenia
G-CSF
Hochster et al. (1994) 21d c.i.v. q28d 14.7 11.3 Neutropenia, 2 PR ovary
thrombocytopenia 1 PR NSCLC
1 PR breast
Plaxe et al. (1993) 24 h c.i.p. q28df 4 3 Neutropenia 5 reduction of ascites
aPaediatricpatients;bforc.i.v. schedulesdosecited is total dose overthe totaltime ofinfusion;cdose forpreviously untreatedpatients without G-
CSF; MTD, 15mgm-2 with G-CSF; drecommended schedule for higher dose intensity; eall leukaemia patients; fc.i.p, continuous intraperitoneal
infusion.
Table IV Topotecan phase II studies
Evaluable Dose schedule Response
Reference Tumour site patients Prior Rx mgm 2 dose-l CR PR %
Giantonio et al. (1993) Prostate 28 Hormones 1.5 x 5 days q2ld 0 1 5
Ilson et al. (1993) Renal cell 15 No CT 1.5 x 5 days q2ld 0 0 0
Kudelka et al. (1993) Ovary 28 All CT 1.5 x 5 days q2ld 0 4 14
Armstrong et al. (1995) Ovary 16 All CDDP 1.5x5 days q2ld 1 3 25
refractory
Chang et al. (1995) Breast 15 0-1 regimens 1.5x5 days q2ld 0 5 33
Eisenhauer et al. (1994) Sarcoma 29 None 1.5 x 5 days q2ld 0 3 10
Eisenhauer et al. (1994) Glioma 31 CT 12 1.5x 5 days q2ld 1 1 7
XRT 24
Creemers et al. (1994) Colon 28 None 1.5x5 days q21d 0 2 7
Sugarman et al. (1994a) Colon 19 Unknown 1.5x5 days q2ld 0 0 0
Creemers et al. (1995) Colon 16 None 0.6 c.i.v. x 21d q 28d 1 0 6
Robert et al. (1994) Head and neck 15 No CT 1.5 x 5 days q2ld 0 4 27
Schiller et al. (1994) SCLC 35 No CT 2.0 x 5 days q 21d G-CSF 0 14 40
Hutson et al. (1995)
Wanders et al. (1995) SCLC 57 All CT 1.5x5 days q2ld 2 7 21
Perez-Soler et al. (1995) SCLC 25 All refractory to 1.25 x 5 days q2ld 0 3 12
etoposide
Weitz et al. (1995) NSCLC 38 No CT 1.5 x 5 days q2ld 0 5 18
36 1.3 c.i.v.x3 d q 28d 0 2 8
Perez-Soler et al. (1994) NSCLC 37 None 1.5 x 5 days q2ld 0 5 14
Lynch et al. (1994) NSCLC 20 None 2.0 x 5 days q21d 0 0 0
Maksymiuk et al. (1995) Mesothelioma 22 None 1.5 x 5 days q2ld 0 0 0
Scher et al. (1994) Pancreas 34 No CT 1.5 x 5 days q2ld 0 4 12
Sugarman et al. (1994b) Pancreas 15 None 1.5 x 5 days q2ld 0 0 0
CT, chemotherapy; XRT, radiation therapy; CR, complete response; PR partial response.Camptothecins in cancer treatment
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cancer have already been identified as tumour types for
randomised studies. In the former, topotecan is being
evaluated in a front-line setting, while in ovarian cancer, a
randomised comparison with paclitaxel in platinum pre-
treated patients has been completed, although results are not
yet available. The findings of this ovarian trial and that of a
phase II study of topotecan in paclitaxel failures will be
important in determining if front-line regimens incorporating
this new drug should be developed further.
At the present time the daily for 5 days schedule appears
to offer the best balance of efficacy and toxicity compared
with 72 h or 21-day c.i.v. schedules, despite preclinical data
favouring prolonged drug exposures. However, the optimal
schedule of administration of topotecan may not yet be
defined and several trials evaluating the activity of the 21-day
infusion are ongoing. The results of these studies may lead to
an interest in chronic oral dosing strategies.
Finally, the evidence of a relationship between total
topotecan AUC and neutropenia (Grochow et al., 1994)
together with recent publication of a limited sampling model
for determining topotecan AUC (Minami et al., 1996) should
lead to prospective studies assessing the pharmacokinetic/
dynamic behaviour of this agent.
9-Aminocamptothecin
Among the many semisynthetic or totally synthetic camp-
tothecin analogues screened, 9-aminocamptothecin was
selected for advanced testing and clinical development
primarily because of its ability to induce complete remissions
in mice bearing human colonic adenocarcinoma and
malignant melanoma cell lines known to be resistant to
standard chemotherapeutic agents (Giovanella et al., 1989,
1991; Pantazis et al., 1992). Like topotecan, pharmacokinetic
and efficacy studies of 9-aminocamptothecin suggested that
maintaining the lactone plasma concentration above a
threshold level for a prolonged period was required for
optimal therapeutic effect (Supko et al., 1993).
The innate aqueous insolubility of 9-aminocamptothecin
resulted in difficulty devising a suitable formulation and
delayed initiation of phase I studies. Two studies of 9-
aminocamptothecin, formulated in polyethylene glycol 400,
phosphoric acid and dimethylacetamide, have been com-
pleted. In both, the drug was given as a 72 h continuous
intravenous infusion either every 2 weeks or every 3 weeks in
patients with advanced solid tumours (Dahut et al., 1994;
Rubin et al., 1994). The 72 h infusion was selected to try to
achieve the prolonged drug concentrations above a 'thresh-
old' level known to be of importance to anti-tumour effect in
animal model systems. Preliminary reports indicate the drug
formation and schedule were well tolerated. Leucopenia was
dose-limiting in both trials. In one study the maximum
tolerated dose (MTD) was S9jg m-2 h-' and the dose was
escalated to 74 jg m-2 h-' with granulocyte colony-stimu-
lating factor (G-CSF). With the highest doses, grade 3
thrombocytopenia as well as nausea/vomiting (controlled
with antiemetics), total alopecia, stomatitis and, infrequently,
diarrhoea were seen. In the 19 patients evaluated in this
phase I study of 9-AC every 2 weeks, there were no objective
responses; minimal responses were evident in patients with
colon, lung and gastric carcinomas (Dahut et al., 1994).
Preliminary pharmacokinetic studies of 9-aminocamp-
tothecin given as a 72 h infusion were done as part of the
phase I evaluation (Takimoto et al., 1994). Steady-state
plasma concentrations increased linearly from 0.89+0.63 nM
to 5.6+0.6 nM over the dose range of 5 to 59 jg m-2 h-'
and total body clearance was 26.5 +8.6 ml min m-2. Non-
linear regression analysis demonstrated biphasic pharmaco-
kinetics for 9-aminocamptothecin lactone with a t1/2, of 1.5-
2.5 h and a t1/2, of 10.7- 12.9 h. Mean steady-state plasma
levels of 9-aminocamptothecin lactone correlated well with
the percentage decrease in granulocyte and leucocyte counts.
Phase II testing of 9-aminocamptothecin as a 72 h infusion
every 2 weeks is ongoing. Furthermore, clinical testing of a
colloid dispersion formulation which improves the aqueous
solubility of 9-aminocamptothecin 20-fold is under way.
Definitive comments on schedule, formulation and efficacy
await the results of these studies.
GI 147211C (GG211)
GI 14721IC (recently renamed GG211) is the synthetic water-
soluble camptothecin analogue, 7-(4-methylpiperazinomethy-
lene)-10,1 1-ethylenedioxy-20(s)-camptothecindihydrochloride.
In comparison with topotecan in vitro, GI 14721 1C is a more
potent inhibitor of topoisomerase I and has greater
cytotoxicity (Kang et al., 1993; Emerson et al., 1995). Anti-
tumour activity was assessed in xenograft models and its anti-
tumour effect was dose schedule-dependent with a greater
reduction in tumour volume achieved by prolonged dosing
(2 x week for 5 weeks). Concurrent experiments demon-
strated that GI 14721IC was slightly more effective than
topotecan in suppressing tumour growth. Preliminary reports
of phase I clinical trials of daily times 5 days and 72 h
infusion schedules are available. On the daily times 5 every 21
day schedule, the maximal tolerated dose was 1.75 mg m-2
day-' in minimally pretreated patients and 1.2 mg m-2 day-'
in heavily pretreated patients (Eckardt et al., 1995). Dose-
limiting toxicities were neutropenia and thrombocytopenia
with no evidence of cumulative toxicity. With the 72 h c.i.v.
schedule, both neutropenia and thrombocytopenia were dose-
limiting at the maximum tolerated dose in pretreated patients
of 2.0 mg m-2 day-' (O'Dwyer et al., 1995). Non-
haematological toxicities seen with both schedules were mild
and included alopecia, anorexia, fatigue, nausea, vomiting,
headache and phlebitis. Responses were seen in patients with
breast, ovary and colorectal cancer who received the drug on
the 72 h c.i.v. schedule.
Combination treatment
Extensive preclinical investigation has led to specific strategies
for combining camptothecins with chemotherapeutic agents
and radiation. In vitro and, for some drugs, in vivo studies
show that the efficacy of camptothecins is synergistic or
additive when compared sequentially with alkylating agents
(cisplatin and cyclophosphamide) (Kano et al., 1992),
topoisomerase II inhibitors (doxorubicin, daunorubicin and
etoposide) (Del Bino et al., 1992) but antagonistic when
combined with the antimetabolite methotrexate. Efficacy of
drug combinations depended not only on choice of drug but
also on schedule as the administration of camptothecins
concurrently with some chemotherapeutic agents leads to
antagonistic rather than synergistic effects (Bertrand et al.,
1992; Kaufmann, 1991).
The combination of irinotecan and cisplatin was superior
to combinations of cisplatin with vindesine or etoposide
against human lung adenocarcinoma cell lines (Kuraishi et
al., 1992). The scheduling of the drugs was critical for success
as sequential administration of camptothecins followed by
cisplatin led to synergistic cytotoxicity while concurrent
administration led to antagonism. Camptothecins may
inhibit topoisomerase I-mediated repair of alkylating agent-
induced DNA damage. There is clinical evidence to support
these laboratory observations. In a phase I trial, toxicity of
topotecan and cisplatin was schedule-dependent. The
administration of cisplatin on day 1 followed by topotecan
daily for 5 days resulted in greater neutropenia and
thrombocytopenia than administration of cisplatin after
topotecan (Rowinsky et al., 1994b). Studies are underway
to determine which regimen possesses superior antineoplastic
effect. In a phase I study of irinotecan with cisplatin, the
partial remission rate was 54% in patients with NSCLC
(Masuda et al., 1992) and in a phase II study of the same
drugs in untreated patients with extensive and limited SCLCthe response rates were 79% and 78% respectively. Although
these two studies do not answer the question of appropriate
timing of drug administration, these results are similar to
standard therapies and suggest that the combination is
effective (Fujiwara et al., 1994).
Synergy was also seen in vitro when camptothecins were
administered sequentially but not concurrently with topoi-
somerase II inhibitors. Pretreatment with irinotecan has been
shown to increase in topoisomerase II mRNA in cells and
cellular overexpression of topoisomerase II is likely to
increase cytotoxicity of topoisomerase II inhibitors (Kim et
al., 1992). In a phase I study of topotecan given by
continuous infusion on days 1-3 and etoposide given over
2 h on days 7-9, sequential sampling of tumours in five
patients was performed. Topoisomerase II levels were
markedly increased immediately before etoposide was given
on day 7 and levels decreased by day 9 in the tumour cells of
one patient who had resolution of malignant ascites (Eckardt
et al., 1994). The concurrent administration of irinotecan and
etoposide yielded a response rate of 21% in a phase II study
of 61 untreated patients with NSCLC (Goto et al., 1995),
which was less than that previously reported in two phase II
trials of irinotecan alone, suggesting that the in vitro data on
scheduling is clinically relevant.
Scheduling effects were also seen when camptothecins were
combined with radiation in tissue culture cell lines. Synergy
was seen only when the drugs were administered shortly after
irradiation suggesting low-dose radiation triggers cells to
enter S-phase rendering them sensitive to the cytotoxic effects
of camptothecins (Mattern et al., 1991; Kim et al., 1992). The
clinical relevance of the synergistic effects of camptothecins
with radiation has not been determined.
Drug resistance and camptothecins
The development of cellular resistance to chemotherapeutic
agents is an important cause of treatment failure in cancer
patients. In the laboratory, at least three well-defined
mechanisms of resistance to topoisomerase I inhibitors have
been described: alteration of topoisomerase I structure or
function; P-glycoprotein (P-gp)-mediated resistance; and, for
irinotecan, reduction of conversion of the prodrug to its
active metabolite.
Qualitative and quantitative alterations of topoisomerase I
are the most significant phenomena causing resistance to
camptothecins. In several normal and malignant tissue
culture lines relative resistance, measured as the increase in
the dose of campotothecin required to produce a given level
of survival compared with parental cells, was between 2- and
350-fold (Andoh et al., 1987; Tanizawa et al., 1993). Point
mutations (Benedetti et al., 1993), deletions (Sugimoto et al.,
1990b) and rearrangements (Tan et al., 1989) in the
topoisomerase I gene have been reported and may be
associated with decreased topoisomerase I levels or activity.
The mutations were contained in well-conserved regions of
topoisomerase I gene and the domains around the mutations
were likely to be critical for enzyme activity and interaction
with camptothecins. Deletions and rearrangements may lead
to structural and functional alterations of the enzyme and
can be accompanied by reduced transcription and enzyme
production. Intriguingly, some cell lines which had alterations
in topoisomerase I levels and activity were more sensitive to
the effects of radiation and topoisomerase II inhibitors
(Sugimoto et al., 1990a). Preliminary experiments indicated
a pattern of cross-resistance among available camptothecins;
however, cross-resistance was not absolute as some cell lines
resistant to topotecan were sensitive to the cytotoxic effects of
irinotecan (Houghton et al., 1993).
Unlike water-insoluble camptothecin and 9-aminocamp-
tothecin, water-soluble derivatives topotecan and irinotecan
may be substrates for P-glycoprotein (Chen et al., 1991).
Both drugs show reduced cytotoxicity measured by IC50
values against MDR, cell lines expressing P-gp (Tsuro et al.,
Camptothecins in cancer treatment
J Dancey and EA Eisenhauer 9
333
1988; Hendricks et al., 1992). However, the relative resistance
to the water-soluble camptothecins was modest compared
with resistance to doxorubicin, vinblastine and etoposide in
the same cell lines.
Two other potentially important mechanisms of resistance
have been described. Reduced conversion of the prodrug
irinotecan to its active metabolite SN-38 caused loss of
efficacy in a cell line selected for resistance to camptothecins
(Niimi et al., 1992). Finally, molecular inhibitors ofapoptosis
such as overexpression of bcl-2 decreased cytotoxicity of
camptothecins (Walton et al., 1993). The clinical relevance of
all of these mechanisms of resistance remains to be
established.
Discussion
Topoisomerase I inhibitors represent a promising new class
of chemotherapeutic agents with a novel mechanism of
action. Renewed interest in their study after the initial failure
of the parent compound in clinical trials 20 years ago has
been driven not only by the understanding of their
mechanism of action, but also by an appreciation of
structure-activity relationships. The broad anti-tumour
activity shown in cell culture and animal studies has been
confirmed in clinical phase I/II evaluation of irinotecan and
topotecan.
Irinotecan has activity in an array of solid tumours but
because of the impressive results in NSCLC and colorectal
carcinoma these two tumour types should be the primary
focus for the development of combination therapy and
randomised trials, at least initially. Preclinical studies have
provided helpful information for the development of
combination regimens and favour sequential administration
of irinotecan with DNA-damaging agents such as cisplatin
and topoisomerase II inhibitors such as etoposide. Irinotecan
and 5-FU in colorectal carcinoma are also an obvious
combination for evaluation and clinical studies are ongoing.
In terms of drug delivery, both the weekly and 3-weekly
schedules have been shown to be effective; which of the two
provides the best therapeutic index is also a question for
comparative trials. In addition to the goal of improving
efficacy in these and other tumour types, attention must be
paid to the toxic effects, especially diarrhoea. Despite
maximal therapy diarrhoea remains problematic and will
need new solutions before irinotecan can be easily assimilated
into routine practice.
Topotecan has a much more favourable toxicity profile
than irinotecan but its spectrum of activity in phase II trials
is somewhat less impressive. Clearly further studies of
topotecan in combination with other effective cytotoxic
agents are warranted in SCLC, head and neck cancer,
ovarian cancer and possibly breast cancer. Its activity in
previously treated ovarian cancer is ofparticular interest. The
results ofthe recently completed phase III trial comparing the
efficacy of topotecan with paclitaxel will be important in
determining the enthusiasm for incorporating topotecan into
front-line ovarian cancer regimens. In SCLC, the role of
topotecan in first-line treatment should be explored and a
study addressing this question is currently ongoing in the
United States. Phase I/II studies are also underway with
topotecan in combination with alkylating agents and
topoisomerase II inhibitors similar to those described for
irinotecan. At the present time the daily for 5 days schedule
appears to offer the best balance of efficacy and toxicity
compared with 72 h or 21 day c.i.v. schedules, despite
preclinical data favouring prolonged drug exposure. How-
ever, clinical studies examining the question of prolonged
administration have been limited to tumour sites in which
topotecan has not shown impressive activity on the daily x 5
day schedule so these may not have been good models in
which to study alternative schedules.
There is no doubt that the clinical data have confirmed
that the camptothecins represent an exciting new class ofCamptothecins in cancer treatment
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chemotherapeutic agents. The role each analogue will play in
improving survival or palliative treatment of specific
malignancies is evolving with the present generation of
randomised trials but this will take several years to unfold.
The data on topotecan and irinotecan have shown how
modifications of the parent molecule lead to substantially
different efficacy and toxicity profiles. Thus, results of phase
II studies with 9-aminocamptothecin and GG 211 will be of
great interest.
An additional aspect of the story of camptothecin
development deserves comment. It is to point out the critical
role that preclinical experiments played in resurrecting the
interest in a class of compounds that would otherwise have
remained abandoned. The identification of a unique
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